Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

Open access

Abstract

Background Invasive candidosis is increasingly prevalent in seriously ill patients. Our aim was to compare micafungin with liposomal amphotericin B for the treatment of adult patients with candidaemia or invasive candidosis.Methods We did a double-blind, randomised, multinational non-inferiority study to compare micafungin (100 mg/day) with liposomal amphotericin B (3 mg/kg per day) as first-line treatment of candidaemia and invasive candidosis. The primary endpoint was treatment success, defined as both a clinical and a mycological response at the end of treatment. Primary analyses were done on a per-protocol basis. This trial is registered with ClinicalTrials.gov, number NCT00106288.Findings 264 individuals were randomly assigned to treatment with micafungin; 267 were randomly assigned to receive liposomal amphotericin B. 202 individuals in the micafungin group and 190 in the liposomal amphotericin B group were included in the per-protocol analyses. Treatment success was observed for 181 (89.6%) patients treated with micafungin and 170 (89.5%) patients treated with liposomal amphotericin B. The difference in proportions, after stratification by neutropenic status at baseline, was 0.7% (95% CI -5.3 to 6.7). Efficacy was independent of the Candida spp and primary site of infection, as well as neutropenic status, APACHE II score, and whether a catheter was removed or replaced during the study. There were fewer treatment-related adverse events--including those that were serious or led to treatment discontinuation--with micafungin than there were with liposomal amphotericin B.Interpretation Micafungin was as effective as--and caused fewer adverse events than--liposomal amphotericin B as first-line treatment of candidaemia and invasive candidosis.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(07)60605-9

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 22 references

Research works printed but not linked: 2

  1. Reboli A, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for treatment of candidaemia and invasive candidiasis. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, USA; 2005. Abstract M-718.
  2. Anaissie EJ, Uzun C, Singer GP, et al. Amphotericin B lipid complex versus amphotericin B for treatment of hematogenous and invasive candidiasis: a prospective, randomized, multicentre trial. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL, USA; September, 1995. Abstract LM21.

Cited by

See all 692

Metadata

Authors
Kuse, E.-R., Chetchotisakd, P., da Cunha, C. A., Ruhnke, M., Barrios, C., Raghunadharao, D., Sekhon, J. S., Freire, A., Ramasubramanian, V., Demeyer, I., Nucci, M., Leelarasamee, A., Jacobs, F., Decruyenaere, J., Pittet, D., Ullmann, A. J., Ostrosky-Zeichner, L., Lortholary, O., Koblinger, S., Diekmann-Berndt, H., & Cornely, O. A.
Affiliations
  • Khon Kaen University (TH)
  • Charité – Universitätsmedizin Berlin (DE)
  • Hospital São Lucas da PUCRS (BR)
  • Dayanand Medical College & Hospital (IN)
  • Grupo Santa Casa de Belo Horizonte (BR)
  • Apollo Hospitals (IN)
  • Onze Lieve Vrouwziekenhuis Hospital (BE)
  • Siriraj Hospital (TH)
  • Erasmus Hospital (BE)
  • Ghent University Hospital (BE)
  • University Hospital of Geneva (CH)
  • Johannes Gutenberg University Mainz (DE)
  • Hôpital Necker-Enfants Malades (FR)
  • Astellas Pharma (Germany) (DE)
  • University Hospital Cologne (DE)
Corresponding author
Cornely, Oliver A
Venue
The Lancet
Publisher
Elsevier BV
Published
2007-05
Volume
369
Issue
9572
Pages
1519-1527
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2121247465
Cited by
692
References
22
Citations by year
2026: 7 · 2025: 12 · 2024: 10 · 2023: 12 · 2022: 9 · 2021: 21 · 2020: 19 · 2019: 29 · 2018: 34 · 2017: 25 · 2016: 25 · 2015: 37 · 2014: 37 · 2013: 43 · 2012: 53
FWCI
51.38
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion)
  • Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
  • Archive ouverte UNIGE (University of Geneva) (submittedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
Keywords
micafungin, liposomal amphotericin B, candidemia, antifungal therapy, treatment success, non-inferiority, neutropenia, adverse events, Candida species
MeSH terms
Micafungin, Adolescent, Adult, Aged, Aged, 80 and over, Amphotericin B, Antifungal Agents, Candidiasis, Double-Blind Method, Female, Humans, Lipoproteins, Male, Microbial Sensitivity Tests, Middle Aged, Peptides, Cyclic, Treatment Outcome, APACHE, Echinocandins, Lipopeptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. https://app.cochat.ai/papers/10.1016/s0140-6736(07)60605-9
The paper
Kuse, E.-R., Chetchotisakd, P., da Cunha, C. A., Ruhnke, M., Barrios, C., Raghunadharao, D., Sekhon, J. S., Freire, A., Ramasubramanian, V., Demeyer, I., Nucci, M., Leelarasamee, A., Jacobs, F., Decruyenaere, J., Pittet, D., Ullmann, A. J., Ostrosky-Zeichner, L., Lortholary, O., Koblinger, S., . . . Cornely, O. A. (2007). Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. The Lancet. https://doi.org/10.1016/s0140-6736(07)60605-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.